Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics

Next Previous
Drug Profile

Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics

Alternative Names: Aloradine IN; Aloradine NS; AM-005; PH-94B; PH94B NS

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Pherin Pharmaceuticals; VistaGen Therapeutics
  • Class Anxiolytics; Behavioural disorder therapies; Small molecules; Steroids
  • Mechanism of Action Chemoreceptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Social phobia
  • Phase II Adjustment disorders

Most Recent Events

  • 09 Jan 2025 VistaGen Therapeutics initiates enrolment in a phase II trial for Social phobia in US (Intranasal, Spray) (NCT06809179, PH94B-CL036)
  • 16 Sep 2024 VistaGen Therapeutics initiates a phase III PALISADE-4 trial for Social phobia (In adults) in USA (Intranasal, Spray) (NCT06615557)
  • 01 Apr 2024 VistaGen Therapeutics initiates phase III PALISADE-3 trial in Social phobia (Intranasal, Spray) in USA (NCT06358651)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top